Want to see SMTI full AI Analyst Report?
Top Page
Sanara MedTech
(NASDAQ:SMTI)
Select Model
Select Model
Rating:59Neutral
Price Target:
$36.00
▲(40.85% Upside)
Action:Reiterated
Date:08/19/26
The score is driven primarily by mixed financial performance—strong growth, very high gross margins, and improving operating/cash flow trends are materially tempered by stressed leverage and weak equity in the balance sheet data. Technicals are supportive but overbought, valuation is constrained by a negative P/E and no dividend yield provided, while the latest earnings call tone and reaffirmed guidance are positive. The pending acquisition is an additional supportive catalyst, subject to deal completion.
Positive Factors
Revenue Growth and Commercial Expansion
Sustained double-digit growth plus broader hospital, facility and distributor coverage indicates rising clinical adoption and a scalable commercial channel. Greater access can support procedure-driven demand and improve salesforce productivity over coming quarters.
Negative Factors
Stressed Balance Sheet and High Leverage
Rising debt alongside a sharply reduced equity base leaves limited financial cushion and increases sensitivity to operational setbacks. High leverage can constrain investment flexibility and make interest obligations more burdensome if growth slows.
Read all positive and negative factors
Positive Factors
Negative Factors
Revenue Growth and Commercial Expansion
Sustained double-digit growth plus broader hospital, facility and distributor coverage indicates rising clinical adoption and a scalable commercial channel. Greater access can support procedure-driven demand and improve salesforce productivity over coming quarters.
Read all positive factors
Sanara MedTech (SMTI) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$316.53M
Dividend YieldN/A
Average Volume (3M)61.65K
Price to Earnings (P/E)―
Beta (1Y)1.25
Revenue Growth12.93%
EPS Growth-219.19%
CountryUS
Employees108
SectorHealthcare
Sector Strength45
IndustryMedical - Instruments & Supplies
Share Statistics
EPS (TTM)-3.72
Shares Outstanding9,188,035
10 Day Avg. Volume48,775
30 Day Avg. Volume61,645
Financial Highlights & Ratios
PEG Ratio-0.02
Price to Book (P/B)33.96
Price to Sales (P/S)1.95
P/FCF Ratio93.17
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda<0.01
Forecast
1Y Price Target
$35.00Price Target Upside36.93% Upside
Rating ConsensusHold
Number of Analyst Covering3
EPS Forecast (FY)0.17
Revenue Forecast (FY)$117.53M
Sanara MedTech Business Overview & Revenue Model
Company Description
Sanara MedTech Inc. is a Fort Worth, Texas-based company established in 2001, dedicated to the development, marketing, and distribution of advanced wound and skin care products. These solutions are provided to a diverse clientele within the United...
How the Company Makes Money
SMTI makes money primarily by selling wound and skin care products to hospitals, outpatient surgery centers, wound care clinics, and other healthcare providers. Revenue is generated through product sales (recognized when products are delivered per...
Sanara MedTech Earnings Call Summary
Earnings Call Date:May 11, 2026
(Q1-2026)
| % Change Since: |
Next Earnings Date:Nov 16, 2026
Earnings Call Sentiment Positive
The call presented a predominantly positive picture: the company delivered strong top-line growth (19% YoY), improved margins, positive GAAP net income, and sizable adjusted EBITDA improvement while expanding commercial reach and reaffirming full-year guidance. Key concerns noted were modest cash reduction, higher interest/other expenses, increased SG&A, and that new sales hires and the Vizient contract will take time to be fully accretive. On balance, the positives (growth, profitability, margin expansion, distribution scale, and cash-based debt servicing) materially outweigh the headwinds.Positive Updates
Strong Revenue Growth
Net revenue increased 19% year-over-year in Q1 2026 (+$4.4M), driven primarily by increased sales of soft tissue repair products including CellerateRX Surgical and BIASURGE.
Negative Updates
Modest Cash Position and Operating Cash Use
Cash decreased to $13.6 million as of March 31, 2026 from $16.6 million at year-end; net cash used in operating activities was $2.5 million in the quarter versus $2.0 million in the prior-year period.
Read all updates
Q1-2026 Updates
Positive
Negative
Strong Revenue Growth
Net revenue increased 19% year-over-year in Q1 2026 (+$4.4M), driven primarily by increased sales of soft tissue repair products including CellerateRX Surgical and BIASURGE.
Read all positive updates
Company Guidance
Sanara reaffirmed Q2 2026 net revenue guidance of $28.5–$29.5 million (up ~10–14% year‑over‑year) and full‑year 2026 net revenue guidance of $116–$121 million (≈13–17% growth). Management said this guidance is supported by a strong Q1 that saw net revenue increase $4.4 million (19% YoY), gross profit rise $4.3 million to $25.9 million (gross margin ~93%, +100 bps), operating income of $2.6 million, adjusted EBITDA of $4.3 million (up 58%), and GAAP net income from continuing operations of $0.4 million ($0.04 per diluted share), while noting a 3‑day shipping shutdown in January and that Q1 is seasonally the slowest quarter. The company highlighted commercial momentum behind the guide—43 sales reps, contracts/approvals in >4,000 hospitals/ASCs, product sales in >1,400 facilities (up from >1,300), >450 distributor agreements (vs 400 a year ago)—and reiterated capital priorities (OsStic market introduction on track for Q1 2027, target R&D run‑rate ~5–7% of sales), with cash of $13.6 million and long‑term debt of $46.2 million.Sanara MedTech Financial Statement Overview
Summary
Income Statement
42
Neutral
Balance Sheet
18
Very Negative
Cash Flow
58
Neutral
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 109.81M | 103.12M | 86.67M | 64.99M | 45.84M | 24.14M |
| Gross Profit | 100.29M | 92.94M | 78.53M | 57.14M | 39.48M | 21.83M |
| EBITDA | 9.46M | 9.03M | -1.86M | -289.10K | -11.57M | -7.22M |
| Net Income | -32.01M | -37.56M | -9.66M | -4.30M | -7.94M | -7.92M |
Balance Sheet | ||||||
| Total Assets | 69.15M | 72.94M | 88.09M | 73.87M | 61.04M | 36.40M |
| Cash, Cash Equivalents and Short-Term Investments | 15.42M | 16.58M | 15.88M | 5.15M | 8.96M | 18.65M |
| Total Debt | 48.53M | 48.19M | 32.29M | 11.79M | 819.22K | 425.44K |
| Total Liabilities | 61.21M | 67.01M | 49.18M | 29.28M | 19.32M | 6.24M |
| Stockholders Equity | 7.94M | 5.93M | 39.40M | 44.83M | 41.83M | 30.64M |
Cash Flow | ||||||
| Free Cash Flow | 4.50M | 2.16M | -253.08K | -3.51M | -6.30M | -5.56M |
| Operating Cash Flow | 5.69M | 6.79M | -23.78K | -3.25M | -5.55M | -4.81M |
| Investing Cash Flow | -5.92M | -8.36M | -6.61M | -10.21M | -3.51M | -5.28M |
| Financing Cash Flow | -1.32M | -8.48M | 17.37M | 9.64M | -627.35K | 28.30M |
Sanara MedTech Technical Analysis
Positive
25.56
Price Trends
27.53
Positive
23.84
Positive
22.75
Positive
Market Momentum
2.06
Positive
80.51
Negative
87.79
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SMTI, the sentiment is Positive. The current price of 25.56 is below the 20-day moving average (MA) of 33.17, below the 50-day MA of 27.53, and above the 200-day MA of 22.75, indicating a bullish trend. The MACD of 2.06 indicates Positive momentum. The RSI at 80.51 is Negative, neither overbought nor oversold. The STOCH value of 87.79 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for SMTI.
Sanara MedTech Risk Analysis
Sanara MedTech disclosed 46 risk factors in its most recent earnings report. Sanara MedTech reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Sanara MedTech Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
78 Outperform | $227.80M | 21.81 | 8.74% | 1.84% | -7.00% | -12.28% | |
69 Neutral | $243.19M | 29.05 | 14.81% | ― | 2.47% | 75.23% | |
59 Neutral | $316.53M | -9.27 | -246.44% | ― | 12.93% | -219.19% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | $267.60M | -5.62 | -21.50% | ― | -18.86% | -0.63% | |
46 Neutral | $142.29M | -5.75 | -145.82% | ― | -5.47% | 13.55% |
* Healthcare Sector Average
SMTI
Sanara MedTech
34.45
1.52
4.62%
INFU
InfuSystem Holdings
12.21
2.34
23.71%
OSUR
Orasure Technologies
3.88
0.74
23.57%
STXS
Stereotaxis
1.42
-1.34
-48.55%
UTMD
Utah Medical Products
71.55
12.39
20.95%
Sanara MedTech Corporate Events
Business Operations and StrategyM&A TransactionsPrivate Placements and Financing
Sanara MedTech agrees to be acquired by MiMedx
Positive
Jul 29, 2026
On July 29, 2026, MiMedx Group Inc. and Sanara MedTech Inc. announced a definitive merger agreement under which MiMedx will acquire all outstanding Sanara shares in a cash-and-stock deal valued at $35 per share, implying an enterprise value of abo...
Executive/Board ChangesShareholder Meetings
Sanara MedTech Shareholders Reaffirm Board and Governance Policies
Positive
Jun 9, 2026
Sanara MedTech shareholders convened on June 4, 2026, for the company’s annual meeting, where 6,701,593 shares of common stock were represented in person or by proxy. Investors elected nine directors, including Seth D. Yon and Ronald T. Nixo...
Business Operations and Strategy
Sanara MedTech Ends Catalyst Advisory Deal, Refocuses Strategy
Neutral
Jun 4, 2026
Sanara MedTech Inc. previously entered into a Transaction Advisory Services Agreement with The Catalyst Group, Inc., effective March 1, 2023, under which Catalyst provided transaction advisory, strategic planning, finance, marketing, and corporate...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.